Diagnostic
Models

Revolutionizing
Cancer Diagnosis
with AiAlpa-Platform

Harnessing The Power Of AI,
Our Pathological Markers Technology 
Transforms Complex Medical Data Into Accurate, Actionable Diagnostics, Paving The Way For More Precise 
And Personalized Cancer Treatment.

What Are
AiAlpa-Platform?

Diagnostic Models of the AiAlpa Platform utilize AI technology to provide analysis results of pathological markers (such as mitosis, TSR, nuclear pleomorphism, HER2, etc.) for various cancers.

Target Cancers & Biamarkers

Target Cancers : Breast cancer, Uterine leiomyoma, Bladder cancer, Neuroendocrine tumors, gastrointestinal stromal tumors
Target biomarkers : Mitosis, TSR, Nuclear Pleomorphism, HER2, etc.

F1 Score 90%

Validation has been completed in collaboration with 12 medical institutions and 100 specialists.

Key Features

Our Pathological Markers Detection

Diagnostic Models

Revolutionizing Cancer Diagnosis
with 
AiAlpa-Platform

Harnessing The Power of AI,
Our Pathological Markers Technology
Transforms Complex Medical Data

Into Accurate, Actionable Diagnostics, Paving The Way
For More Precise And Personalized Cancer Treatment.

What Are
AiAlpa-Platform?

Diagnostic Models of the AiAlpa Platform
utilize AI technology to provide analysis results of
pathological markers (such as mitosis, TSR,
nuclear pleomorphism, HER2, etc.) for various cancers.

Target Cancers &
Biomarkers

Target Cancers : Breast cancer, Uterine leiomyoma, Bladder cancer, Neuroendocrine tumors, gastrointestinal stromal tumors

Target biomarkers : Mitosis, TSR, Nuclear Pleomorphism, HER2, etc.

F1 Score 90%

Validation has been completed in collaboration with
12 medical institutions and 100 specialists.

Key Features

Our Pathological Markers Detection


The ability to simultaneously analyze multiple pathology slides reduces the time required to process large volumes of data. 

This feature is particularly beneficial for pathologists handling extensive datasets, greatly enhancing the efficiency of the analysis process.


The location with the highest Mitosis distribution is intuitively displayed, helping pathologists easily identify the TOP HPF (High-Power Field). This feature provides clear data visualization, offering valuable insights to users.


The Mitotic Rate and severity of cancer are intuitively displayed in a summary format for easy viewing. This feature visually represents complex data in a clear manner, allowing pathologists to quickly grasp the necessary information, significantly improving workflow speed and efficiency.


Auto Segmentation identifies the Region of Interest (ROI) for analysis. This maximizes AI processing speed for large datasets, significantly reducing the time required for the analysis process.


It is possible to select various cancer types and corresponding biomarkers, offering flexibility that allows each pathologist to work in an environment best suited to their specific needs.

Additionally, multiple cancer types and different AI models can be applied in real time. This flexibility enables pathologists to work in the most appropriate environment based on their unique requirements.

In The Moment That
Changes The World,
MTS Stands At The Center

MTS

MTS COMPANY | Biz Licence 513-88-00391

Tel. 02. 501. 1980 | help@mtsco.co.kr

Addr. 434, Samseong-ro, Gangnam-gu, Seoul, South Korea


Copyright ©️ MTS Company CO., LTD. All rights reserved.

In The Moment That Changes The World,
MTS Stands At The Center

MTS COMPANY | Biz Licence 513-88-00391

Tel. 02. 501. 1980 | help@mtsco.co.kr

Addr. 434, Samseong-ro, Gangnam-gu, Seoul, South Korea


Copyright ©️ MTS Company CO., LTD. All rights reserved.

Click to move to other product